middle.news
Immuron builds cash and clinical optionality after record FY26 sales
4:53pm on Thursday 24th of September, 2026 AEST
•
Biotechnology and pharmaceuticals
Read Story
Immuron builds cash and clinical optionality after record FY26 sales
4:53pm on Thursday 24th of September, 2026 AEST
Key Points
A$7.7 million FY26 revenue, up 6%
Net loss narrowed to A$3.68 million
Cash rose to A$9.02 million after equity funding
FDA-cleared IMM-529 IND advances towards Phase 2
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immuron (ASX:IMC)
OPEN ARTICLE